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Thromboxane in the pathogenesis of glomerular injury in diabetes. The
present study examined the role of thromboxane (TX) in the initiation
and progression of glomerular injury in diabetic rats, as reflected by
albuminuria and glomerular histology. Urinary thromboxane and albu-
min excretion (UTX and UAIb) were elevated by four months after
induction of diabetes in the moderately hyperglycemic (200 to 400 mg/dI
glucose) streptozotocin diabetic rat (SDR) compared to age-matched
control rats. UTX and UAb both increased progressively in SDR over
the seven month period of study. Glomerular TX production, glomer-
ular volume, fractional and absolute mesangial volume and glomerular
basement membrane (GBM) width were also increased after seven
months in SDR compared to control. Treatment of SDR with a
thromboxane synthetase inhibitor (TXI) 4' (imidazol-l-yl) acetophenone
(100 mg/kg/day) for seven months beginning at the time of induction of
diabetes prevented the increases in UTX, UAIb, glomerular TX produc-
tion, glomerular volume and mesangial volume and attenuated, but did
not prevent, GBM thickening. When the same dose of the TXI was
begun five months after induction of diabetes and continued for two
months, UTX and ex vivo glomerular TX production were reduced by
only 60% compared to untreated SDR and remained higher than
corresponding values in control rats. Delayed treatment with the TXI
alone did not alter UAIb compared to untreated SDR. By contrast,
treatment of five month albuminuric SDR for only two months with the
TXI plus the TX receptor antagonist (TXRA) Bay U 3405 (5 mg/kg/day)
prevented a further increase in UAIb, and reduced fractional albumin
clearance and mesangial volume compared to values in untreated SDR.
Combined treatment with the TXI and TXRA had no effect on GBM
width or glomerular volume compared to values in untreated SDR. The
results support roles for TX in the initiation of, and for TX and/or
endoperoxides in the progression of glomerular injury in SDR.
Thromboxane (TX) has been implicated as one of the medi-
ators of increased glomerular permeability to albumin in exper-
imental murine models of diabetic nephropathy [1—5], renal
mass ablation [6], spontaneous progressive kidney disease [7,
8], nephrotoxic nephrosis [9], and late nephrotoxic serum
glomerulonephritis [10]. Limited studies in humans also suggest
a role for TX in the pathogenesis of diabetic nephropathy
[11—15], lupus nephritis [16], eclampsia [17], and cyclosporine
nephrotoxicity [18]. Results from our own and other laborato-
ries have demonstrated that urinary TX excretion (UTX) and
glomerular TX production are elevated concurrent with the
development of albuminuria in the streptozotocin diabetic rat
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(SDR) [1, 4, 19—22]. Treatment of SDR with a TX synthetase
inhibitor (TX!), 4' (imidazol-l-yI) acetophenone beginning at the
time of induction of diabetes prevents or delays the increases in
UTX, urinary albumin excretion (UAIb), and fractional clearance
of albumin which otherwise develop in this model. Similar
results have been obtained with a genetic model of diabetes in
the mouse [2]. The present study further examined the role of
TX in the initiation and progression of glomerular injury in
SDR, as reflected by albuminuria and glomerular histology.
Methods
Treatment of rats
Female Sprague-Dawley rats (180 to 200; Zivic-Miller Labo-
ratories, Pittsburgh, Pennsylvania, USA) were age and weight
matched and placed in one of seven groups of 12 rats each as
follows: Group I, non-diabetic controls; Group II, diabetic;
Group III, diabetics treated with the TXI 4' (imidazol-l-yl)
acetophenone beginning one day after the induction of diabetes
and continuing for seven months; Group IV, diabetics treated
with TX! beginning five months after the induction of diabetes
and continuing for an additional two months; Group V, diabet-
ics treated with TXI plus the TXRA Bay U 3405 beginning five
months after the induction of diabetes and continuing for an
additional two months; Group VI, non-diabetics treated with
TX! for seven months; Group VII, non-diabetics treated with
TX! plus Bay U3405 beginning at month 5.All non-diabetic rats
received 1 mI/kg body weight of the vehicle (sterile 0.010 M
citric acid in saline solution, pH 4) by tail vein. Diabetic rats
received 60 mg/kg streptozotocin in the vehicle. Only strepto-
zotocin treated rats with blood glucose higher than 300 mg/dl
glucose 24 hours after injection of streptozotocin were included
in the study. All diabetic rats received heat treated ultralente
insulin (Novo Pharmaceuticals, Copenhagen, Denmark), 2 to 5
U/rat/day subcutaneously, beginning 24 hours after streptozo-
tocin injection and continuing for the entire seven month study
period. Blood glucose was determined at two week intervals
with a blood glucose meter (Diascam-S; Home Diagnostics,
Inc., Eatontown, New Jersey, USA) and the insulin dose
adjusted, if necessary to maintain values between 200 and 400
mg/dl. Rats treated with 4' (imidazol-l-yl) acetophenone re-
ceived 100 mg/kg/day in 0.2 ml of olive oil. Rats treated with
Bay U 3405 received 5.1 0.1 mg/kg/day in the drinking water.
The volume of water consumed by the rats being treated with
Bay U 3405 was measured daily and the average dose calculated
937
938 Craven et a!: Thromboxane and glomerulopathy
based on the water consumed. All rats consumed ad libitum a
standard Tekiad Premier diet which contained 24.48% protein.
At the initiation of the study and then at monthly intervals,
rats were placed in metabolic cages and 24-hour urine collec-
tions were made on ice. Urine was frozen and used for
determination of albumin, TXB2 and [14C] inulin clearance.
Measurement of blood pressure
Systolic blood pressure was measured at 30 day intervals for
90 days before sacrifice in conscious rats with an electrosphyg-
mograph and microphone cuff pump (Narco Biosystems, Hous-
ton, Texas, USA). At least four blood pressure readings were
taken in each rat at each assessment.
Determination of urinary albumin excretion
Urine albumin was determined by an enzyme linked immuno-
sorbent assay as previously described [1]. Rabbit anti-rat albu-
min (immunoglobulin G fraction) and peroxidase conjugated
rabbit anti-rat albumin were obtained from Organon-Teknika-
Cappel, West Chester, Pennsylvania, USA and diluted 10,000
and 600 times, respectively. Heat-inactivated normal rabbit
serum (Organon-Teknika-Cappel, 10% in saline solution) was
used as a blocker. Standard curves were linear between 40 and
0.5 ng albumin per well.
Determination of urinary excretion and glomerular
production of TXB2
Glomeruli were isolated and incubated for 30 minutes in
Krebs Ringer bicarbonate buffer containing 100 mg/dl glucose
as previously described 4]. TXB2 released into the incubation
media was determined by radioimmunoassay as previously
described [1] by using reagents purchased from Dupont, NEN,
Boston, Massachusetts, USA. Samples were extracted by the
method of Powell [23] before assay. Recovery of TXB2 from the
extraction procedure was 60 to 70%, and the results were
corrected accordingly. The procedures used to validate mea-
surements of urinary TXB2 excretion have been previously
described [1]. Cross reactivity of the 2,3 dinor derivative of
TXB2 in the TXB2 assay was 100%. 1 l-Dehydro TXB2 demon-
strated 1% cross reactivity with the TXB2 anti-serum.
Determination of C,,,, CA/b, and fractional CA/b
Inulin clearance (C1,,) was determined just before sacrifice at
seven months from the clearance of [t4C] inulin given by
osmotic minipump as previously described [4, 24]. C1,,, albumin
clearance (CAIb) and fractional CAIb were calculated from
measurements of 24 hour urinary albumin and ['4C1 inulin
excretion, plasma albumin and plasma ['4C] inulin.
Determination of efficacy of Bay U3405 as a TX receptor
antagonist
The efficacy of Bay U3405 as a TXRA was determined in
preliminary studies by assessing its effect on the reduction in
C1,, induced by the TX/prostaglandin endoperoxide mimetic
U466l9 [(15S)-hydroxy-l 1 alpha, 9 alpha (epoxymethano)
prosta-5z, 13 E-dienoic acid] in control rats. C1,, was measured
as described above on three consecutive days in three groups of
three rats each. The groups received 5 mg/kg/day, 10 mg/kg/day
or no Bay U3405 in the drinking water starting 24 hours before
the start of the clearance measurements. After three days, a
second osmotic minipump which delivered 86 jsg/day of U46619
was inserted into all the rats. C1,, was then determined for an
additional three consecutive days. In the absence of pretreat-
ment with the TXRA, U466l9 reduced C1,, from 7.8 1.1
ml/min/kg to 4.5 0.6. Prior administration of either 5 or 10
mg/kg/day of Bay U3405 prevented the decline in C1,, induced
by U466l9 infusion. Accordingly, the lower dose of the TXRA
was employed in the current studies.
Morphometric measurements
GBM width and fractional volume of glomerular components
were determined by electron microscopy (EM) of renal cortical
samples from rats in Groups I, II, III and V. Renal cortical
tissue was minced with a razor blade and fixed in 2% paraform-
aldehyde in 0.1 M sodium phosphate buffer, pH 7.4. The tissues
were washed in 0.1 M sodium phosphate buffer, pH 7.4 and
post-fixed in 1% osmium tetroxide. The segments were dehy-
drated in graded alcohols and embedded in Spurr' s embedding
medium (Electron Microscopy Sciences, Fort Washington,
Pennsylvania, USA). Ultrathin sections were stained with
uranyl acetate followed by aqueous lead citrate and examined
by transmission electron microscopy (Philips EM-300; Philips
Electronic Instruments, Mahwah, New Jersey, USA). EM
studies were performed on seven (group I), 15 (group II), nine
(group III) and 25 (group V) glomeruli from four rats in each
group. GBM width was measured by the method of orthogonal
intercepts as previously described [25]. Electron micrographs
with magnification of 7392 x were employed. A grid with five
equally spaced horizontal and vertical lines was placed over
each electron micrograph and a measurement made with a
micrometer at each point where a line on the grid intercepted
the endothelial-GBM interface. GBM is measured on a line
orthogonal to the GBM at the edge of the endothelial-GBM
interface [25]. Sixty-two 5 measurement of GBM were made
on each rat.
Fractional volume of glomerular components was determined
as previously described [24, 25] by placing a 68 point grid over
each electron micrograph and determining the number of points
falling on mesangial cells plus matrix, capillary lumen, epithelial
cells plus basement membrane and endothelial cells. At least
400 points were evaluated for each rat. Electron micrographs of
magnification 7392 x were employed for the measurements.
Glomerular volume (Vs) was calculated from glomerular cross
sectional area (AG) as determined by light microscopy on an
average of 118 glomeruli from each group. Measurements were
made at a magnification of 100 x. The formula VG = B/k (AG)3t2
was used for the calculation. B = 1.38, the shape coefficient for
spheres and k = 1.1 is a size distribution coefficient [26].
Absolute volume of glomerular components was calculated as
the product of the fractional volume of each component and the
glomerular volume (VG).
All samples were randomized and examined in a coded
fashion so that the pathologist was not aware of the treatment
groups from which the sample came.
Statistical methods
The significance of differences between more than two mean
values was determined by analysis of variance (ANOVA)
followed by the Fisher PLSD test. Where appropriate non-
parametric (Wilcoxon rank sum test) methods were used [27].
Differences between mean values were judged to be significant
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at P < 0,05. With the exception of UTXB, excretion, all other
parameters monitored in the present study did not differ from
those in untreated non-diabetic rats compared to the non-
diabetic rats which received either TXI or TXI plus TXRA.
Accordingly, data from only the untreated non-diabetic controls
(Group I) were employed for purposes of statistical comparison
and are presented.
Results
Figure 1 shows the effects of treatment of diabetic rats with a
TXI alone or with the TXRA, Bay U3405 on blood glucose,
body and kidney weight. The mean blood glucose values
obtained at two week intervals for the study groups are shown.
There were no significant differences in the mean blood glucose
values among the four diabetic rat groups. Blood glucose values
were all significantly higher in the diabetic rat groups compared
to values of age matched control rats. Body weights at sacrifice
were modestly but significantly reduced in all the diabetic
groups compared to control. However, there were no signifi-
cant differences among the diabetic groups. As is also shown in
Figure 1, mean kidney weight at sacrifice was higher in the
diabetic rats compared to values for age matched controls,
Kidney weights also did not differ among the diabetic groups.
Systolic blood pressure was not significantly different in seven
month SDR versus age matched controls (Control, 118 6;
SDR, 124 7 mm Hg). Treatment of SDR for two or seven
months with the TX! or for two months with the TXI plus
TXRA had no effect on systolic blood pressure (not shown).
Figure 2 illustrates the time course of changes in UAIb and
UTxB2 in the five treatment groups during the seven months of
observation. By four months after induction of diabetes, UA,b
and UTXB2 were significantly elevated in untreated SDR com-
pared to age matched control rats, and continued to rise until
sacrifice at seven months. UAIb was modestly elevated in the
control rats by six months compared to values at earlier times in
the same rats, whereas UTxB2 did not change in the nondiabetic
rats during the course of study. Consistent with previous
observations, treatment of SDR with TX! beginning one day
after the induction of diabetes and continuing to sacrificie,
completely prevented the rise in UAIb and UTxB2 otherwise seen
in untreated SDR.
As is also shown in Figure 2, treatment of albuminuric five
month SDR for two months with the same daily dose of TXI
that was effective in preventing increases in UTxB, and UAIb
when given at the onset of diabetes reduced UTXB, significantly
at six and seven months compared to corresponding values in
untreated SDR. However, UTxB2 of SDR treated for only two
months with the TXI remained two fold higher than that of
control rats. Moreover, after five months of diabetes, treatment
of SDR with TX! alone for two months failed to alter UAIb
compared to corresponding values in untreated SDR at months
six and seven.
By contrast, as is also shown in Figure 2, combined treatment
of SDR with TX! plus the TXRA, Bay U3405 initiated after five
months of diabetes prevented the progressive increase in UAIb
and resulted in significantly lower values of UAIb at six and
seven months compared to those observed in untreated SDR.
Nevertheless, UAIb of SDR treated with TX! plus the TXRA
remained significantly higher than corresponding values in age
matched non-diabetic rats. Consistent with results from SDR
treated with TX! alone after five months of diabetes, UTXB, was
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Fig. 1. Effects of treatment of SDR with a thromboxane synthetase
inhibitor (TX!) and TX receptor antagonist (TXRA) on blood glucose
concentration, body weight and kidney weight. Values shown represent
means sr of determinations of blood glucose at 2 week intervals
during the Ito 7 month study period. Body weights and kidney weights
were obtained at sacrifice after 7 months. Group 1, non-diabetic
controls; Group 11, 7 month untreated SDR; 7 month SDR treated with
TXI for 7 months; Group IV, 7 month SDR, TX! for 2 months; Group
V, 7 month SDR, TXI plus TXRA for 2 months. Values are means SE
with N = 12 in each study group. *Differences in mean values are
significant at P < 0.05 compared to Group I.
reduced at six and seven months in rats treated with TX! plus
TXRA compared to untreated SDR, but remained significantly
elevated compared to the initial values (1 to 3 months) in the
same group of SDR or to values of age matched control rats.
Figure 3 shows the individual values for UAIb for months 5, 6
and 7 of diabetes in untreated SDR (upper panel) and SDR
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Fig. 2. Effects of TX! and TXRA on (A) urinary albumin and (B)
thromboxane excretion in SDR. Symbols are: (•) 7 mo D; (O) 7 mo D,
2 mo TX!; (U) 7 moD, 2 mo TX! + TXRa; (El) 7 mo C; (D) 7 mo D, 7
mo TX!. *Differences in mean values are significant compared to
corresponding values in the same rats at I month, when tested by
ANOVA/Fisher PLSD or Wilcoxon rank sum test; P < 0.05 vs. I mo.
#Differences in mean values are significant compared to corresponding
values in 7 month untreated diabetic rats (7 mo D) when tested by
ANOVA/Fisher PLSD or Wilcoxon rank sum test; P <0.05 vs. C. (N
= 12).
treated with TX! plus Bay U 3405 (lower panel). UAIb in the
untreated SDR after six or seven months of diabetes were
higher than values obtained in the same rats after five months of
diabetes. By contrast, no further increase in UAb occurred after
six or seven months of diabetes in SDR treated during this
period with TX! plus TXRA, compared to values in the same
group of rats after five months of diabetes.
Figure 4 shows the effects of a TX! and TXRA on C1, CAIb
and fractional CAIb in SDR at seven months. Although some-
what higher, C1 did not differ significantly in untreated SDR
after seven months of diabetes compared to age matched
control rats. However, in SDR treated with a TX! plus TXRA
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Fig. 3. Effects of treatment ofdiabetic rats with a TXI and TXRa on
individual values for urinary albumin excretion. *Differences between
mean values are significant at P < 0.05 when compared to correspond-
ing values at 5 months by ANO VA/Fisher PLSD or Wilcoxon rank sum
test (N = 12).
during months six and seven, C was significantly higher than
control. As is also shown in Figure 4, CAIb and fractional CAIb
were higher in both treated and untreated SDR compared to age
matched controls. However, CAIb and fractional CAIb were
significantly reduced in SDR treated with a TX! plus TXRA
compared to untreated SDR. C1, CAIb and fractional CAIb of
seven month SDR treated with the TX! alone during months 6
and 7 did not differ from corresponding values in untreated
seven month SDR (Group !V, GFR 8.9 0.7 mI/mm/kg; CAJi, 56
9 x l0 mi/mm/kg; CAJb/Cjfl,6.3 0.7 x iO. Treatment of
SDR for the entire seven months with the TX! resulted in values
for GFR which were not significantly different from those in
untreated SDR, but completely prevented the increase in CAIb
and fractional CAIb seen in the untreated SDR (Group III, GFR,
11.8 2 mI/mm/kg; CAIb, 2 0.2 ml/min/kg x i0; fractional
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CAIb 0.17 0.01 x 10—k). Treatment of non-diabetic rats for
two or seven months with TXI alone or for two months with
TX! plus TXRA did not alter C1, UAIb, CAIb or fractional CAIb
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Fig. 5. Effects of TXI treatment of diabetic rats on cx vivo glomerular
TXB2 production. Glomeruli were isolated at sacrifice from renal
cortices of control (C) and diabetic (D) rats which had been untreated (7
mo D), treated for 2 or 7 months with the TXI or treated for 2 mo with
the TXI plus TXRA. Values represent means SE. Glomeruli isolated
from 4 rats were pooled for a single determination of TX production (N
= 3 for each experimental group). *Differences in mean values are
significant at P < 0.05 compared to 7 month control, by independent
ANOVA/Fisher PLSD. #Differences in mean values are significant at?
< 0.05 compared to untreated 7 month diabetic rats.
compared to corresponding values in untreated age-matched
non-diabetic rats (not shown).
Figure 5 compares ex vivo TXB2 production in glomeruli
isolated from untreated seven month SDR, diabetic rats treated
for either the final two or entire seven months with the TX! and
age matched control rats. Glomerular TX production was
higher in untreated SDR compared to controls. In SDR treated
for the entire seven months with a TX!, glomerular TXB2
production did not differ from control. By contrast, analogous
to results obtained with measurements of UTX, treatment of
SDR for only two months with the TXI or with the TX! plus the
TXRA significantly reduced glomerular TX production com-
pared to the value in untreated SDR, but TX production
remained higher than control levels.
Table 1 shows values for glomerular volume (V0), fractional
and absolute volumes of glomerular components and GBM
width in relevant study groups. Representative electron micro-
graphs are shown in Figures 6 and 7. V0 was significantly
increased in untreated SDR compared to values in non-diabetic
age-matched controls. Treatment of SDR for seven months with
the TX! prevented the increase in V0. By contrast, treatment of
SDR for only two months with the TX! plus TRA did not alter
the increase in V0 compared to that of untreated SDR. Frac-
tional and absolute mesangial volume were both increased in
seven month untreated SDR compared to values obtained in
Fig. 4. Effects of a TX! and TXRa on (A) C,,, (B) CA/b and (C)fractiona!
CA/bin diabetic rats. Values shown are mean SE with N = 12 for each
group. Where indicated on the vertical axis, values shown have been
multiplied by i0. *Differences between mean values are significant at
P < 0.05 compared to 7 month control rats by ANOVA/Fisher PLSD or
Wilcoxon rank sum test. #Differences between mean values are signif-
icant compared to 7 month diabetic rats at P < 0.05 by ANOVA/Fisher
PLSD or Wilcoxon rank sum test.
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Table 1. Effects of treatment of SDR with a TX synthetic inhibitor (TX!) annd TX receptor antagonist (TXRA) on glomerular morphology
Treatment groups
Va
p.m3 x 1O M + MC
Fractional volume %
EC + GBM Endo CL
7 months Non-diabetic
7 months Diabetic-untreated
7 months Diabetic, 7 months TXI
7 months Diabetic, 2 months TXI + TXRA
0.77 0.11 14 3
2.0 0.3a 31 4
1.0 02b 14 3"
2.3 0.3a 20 2"
45 634 2
41 342 0
4 1
3 2
1.3 0.7
0.7 0.3
37 0.330 344 5'
37 3
Table 1. Continued
Absolute volume p.m3 X 1O
VM+MC VEC+GBM VEfldO VCL GBM nm
0.11 0.005 0.35 0.04 0.031 0.009 0.28 0.001
0.65 0.005k 0.68 0.05a 0.06 0.04 0.60 0.05k'
0.14 OO3 0.41 003b 0.013 0.007 0.44 o.o5
0.46 009a,b 0.97 0.016 0.008 0.85 006a,b
207 13341 7
261 4a,b
383 7
Values shown are means SE; n = 4 in each study group. Abbreviations are: Glomerular volume, V0; M + MC, mesangial matrix plus mesangial
cells; EC, epithelial cells; Endo, endothelial cells; CL, capillary lumen; GBM, glomerular basement membrane; M+MC, absolute volume of the
mesangial matrix plus mesangial cells; EC+GBM, absolute volume of epithelial cells plus GBM; VEfld,, absolute volume of endothelial cells; VCL,
absolute volume of the capillary lumen. Where indicated values shown were multiplied by 10".
Symbols are: a Means are significantly different at P < 0.05 compared to corresponding values in non-diabetic rats.
b Means are significantly different at P < 0.05 compared to corresponding values in untreated diabetics.
control rats. Although the fractional volumes of epithelial cell
(EC) plus GBM, capillary lumen (CL) and endothelial cells
(Endo) were all lower in untreated SDR compared to controls,
these differences did not achieve statistical significance (Table
1). Absolute volumes for EC plus GBM and CL were signifi-
cantly higher in the untreated SDR compared to control due to
the larger glomerular volumes in the diabetics. By contrast, no
significant difference in absolute volume of endothelial cells was
observed. Treatment of SDR with the TXI starting one day after
the induction of diabetes prevented the increase in fractional
and absolute mesangial volume seen in SDR. Fractional volume
of CL was increased in diabetic rats treated with the TX! for
seven months compared to untreated diabetics, whereas frac-
tional volumes of EC plus GBM and Endo were not significantly
different in these two groups. Absolute volume of EC plus
GBM, Endo and CL were reduced in diabetic rats treated for
seven months with the TX! compared to values observed in
untreated diabetics. However, this change only achieved sta-
tistical significance in the case of EC plus GBM. In SDR with
established albuminuria, treated for two months with TX! plus
TXRA, fractional and absolute mesangial volume were signifi-
cantly reduced compared to the values in untreated SDR.
However, whereas fractional volume of the mesangium of SDR
treated for only two months with the TX! plus TXRA was not
significantly different from values in age matched non-diabetic
rats, values for absolute mesangial volume remained signifi-
cantly higher in diabetic rats treated with TX! plus TXRA than
those in age matched non-diabetic rats. Fractional volume of
EC plus GBM, Endo and CL were not significantly different in
diabetic rats treated with TXI plus TXRA compared to un-
treated diabetic rats. Absolute volume of the EC plus GBM and
CL were, however, significantly higher in diabetic rats treated
for only two months with the TXI plus TXRA compared to
corresponding values in non-diabetic rats, due to the larger
glomerular volume of this diabetic group. GBM width was
increased in SDR. Treatment of SDR for seven months with
TXI attenuated the increase in GBM width compared to values
in untreated SDR. However, values remained significantly
higher than those in control rats. By contrast, treatment for
only two months with the TX! plus TXRA was without effect on
GBM width compared to values in untreated diabetic rats.
Discussion
In human diabetic nephropathy, the development of clinical
proteinuria is well correlated with structural changes in the
glomerulus, and has been reported to correlate best with
expansion of mesangial volume rather than with GBM thicken-
ing [28]. Although neither the severely or moderately hyper-
glycemic SDR demonstrates a histologic pattern of nodular
glomeruloscierosis characteristic of advanced human diabetes,
development of proteinuria in SDR occurs at an accelerated
rate relative to age-matched non-diabetic controls, and has been
correlated with expansion of mesangial volume [29]. In this
regard, mesangial expansion has been a consistent finding in the
non-insulin treated, severely hyperglycemic SDR [30—32].
However, mesangial expansion has been less pronounced [26]
or not observed [33] in moderately hyperglycemic SDR treated
with insulin. In the present study the degree of mesangial
expansion was much greater than that previously reported in
the moderately hyperglycemic SDR [26]. The reason(s) for this
are not clear. Differences in blood pressure, protein intake or
gender of the rat used are possibilities. Thus, in one previous
study [33] moderately hyperglycemic diabetic rats experienced
a significant fall in blood pressure compared to controls. The
reduction in blood pressure might have prevented morphologic
injury in those rats [331. In the present study, blood pressure did
not differ between moderately hyperglycemic SDR and age
matched control rats. A second difference between the present
and previous studies is the gender of the rats employed. Female
rats were used in the present and previous studies from our
laboratory [1, 4] to avoid prostatic contributions to urinary
prostaglandins. Both previous studies which found a lesser
degree or no mesangial expansion employed male rats [26, 33].
In this regard, we could find no previous studies comparing
7 Month diabetic —7 month TXI 7 Month diabetic —2 month TXRa + TXI
Fig. 6. Electron micrograph illustrating representative glomerular histology in renal cortical sections obtained from rats in the indicated
experimental groups (x3696).
glomerular morphology in male versus female diabetic rats.
However, there is evidence in humans to suggest that the onset
of nephropathy in type I female diabetics may be earlier than in
males [34]. A third potential difference between the present and
previous studies is the amount of dietary protein consumed by
the rats. Specifically, a higher protein intake by rats in the
present study may have accelerated glomerular injury 1331.
Unfortunately, we did not monitor food intake.
7 Month control 7 Month diabetic
iAnTE rB C3
944 Craven et a!: Thromboxane and glomerulopathy
7 Month control 7 Month diabetic
Fig. 7. Electron micrographs representing peripheral glomerular basement membranes in rats from the indicated experimental groups (X 14,520).
Earlier studies from our own and other laboratories have
demonstrated increased urinary excretion of TX in experimen-
tal diabetes [1, 2, 4, 19—22] and have supported a pathogenetic
role for TX in diabetic and other glomerulopathies [1—10]. We
have previously reported that glomerular production of PGE2
and 6-keto-PGF1 are elevated by one week after induction of
diabetes and remain elevated for at least two months in mod-
erately hyperglycemic diabetic rats [19, 35]. The increase in
glomerular synthesis of vasodilatory prostaglandins is associ-
ated With elevations in C1. Treatment of moderately hypergly-
cemic diabetic rats with aspirin for two months suppressed
glomerular production of PGE2 and 6-keto-PGF1 to control
values and reduced GFR, supporting a role for vasodilatory
prostaglandin in the elevation of GFR [19]. However, urinary
POE2 excretion [4], glomerular POE2 and 6-keto-PGF1, pro-
duction [1] and C1 [1, 4] are not significantly elevated in the
moderately hyperglycemic diabetic rat at six months after
induction of diabetes. Moreover, treatment of rats with the TXI
for nearly six months, at a dose which prevented the increase in
UTXB2 and albumin excretion otherwise seen in diabetic rats,
had no significant effect on urinary excretion of POE2 [4] or
glomerular POE2 or 6-keto-PGF1 production [1]. Thus, al-
though our data do not exclude a role for the early increase in
vasodilatory prostaglandins and the associated glomerular hy-
perfiltration in the pathogenesis of diabetic nephropathy, there
is clearly no correlation between enhanced glomerular produc-
tion or urinary excretion of vasodilatory prostaglandins and the
development of albuminuria or mesangial expansion. By con-
trast, glomerular TX production increases as early as one week
after induction of diabetes in SDR and remains elevated [34].
Thus, TX may play a role in both the initiation and progression
of glomerular injury.
Several previous studies [1, 4, 19, 22] support glomeruli as
the source of increased urinary TXB2 excretion in the diabetic
rat. Nevertheless, not all studies of glomerular TXB2 produc-
tion in diabetes have yielded consistent results. Schambelan et
al [36] reported increased conversion of exogenous, labeled
arachidonate to POE2, PGF2, POD2 and TXB2 in glomeruli
from untreated 9 to 23 day diabetic rats. Both basal PGE2 and
TXB2 were increased in diabetic glomeruli when assessed by
radioimmunoassay, but the change was only significant with
respect to PGE2. Bunke and Itskovitz [21] reported an increase
in urinary TXB2 excretion 2 to 14 weeks after induction of
diabetes, but no change in glomerular or papillary TXB2 pro-
duction when assessed ex vivo in untreated severely hypergly-
cemic diabetic rats (763 mgldl glucose). Administration of
insulin and resultant attenuation of hyperglycemia (520 mgldl)
resulted in an increase in cx vivo glomerular TXB2 production
to values higher than control rats or diabetic rats which did not
receive insulin. Glomerular PGE2 generation was not different
in the diabetic rats treated with low doses of insulin compared
to controls [21]. Quilley and McGiff [20] reported increased
urinary excretion of TXB2 in untreated diabetic rats between 48
hours and 176 days after induction of diabetes. However, in a
separate study [36] renal venous effluent TXB2, measured in the
presence of exogenous arachidonate, was not significantly
higher in the diabetic compared to control rats. Collins et al [22]
demonstrated increased renal venous effluent TXB2 in the 8—11
week untreated diabetic rat and found it to be increased in
diabetic rats fed a 60% protein diet compared to control rats fed
a 24% protein diet or diabetic rats fed an 8% protein diet.
However, since they did not report values for TXB2 in diabetic
rats fed a 24% protein diet, it is not possible to discern from
their data whether the increase in TXB2 was due to an increase
in dietary protein or to the diabetic state per se. The reasons for
these differences are not clear, but may be related to duration
and severity of diabetes, protein content of the diet, method of
sampling and the presence or absence of exogenous arachido-
nate.
The present study suggests that increased glomerular TX
production may be involved in the pathogenesis of mesangial
expansion in SDR, and that TX and/or endoperoxide may
participate in both the initiation and progression of glomerular
injury in this experimental model of diabetes. Thus, treatment
of SDR with a TXI for seven months beginning from the time of
induction of diabetes prevented the progressive increases in
both urinary excretion of TX and albumin otherwise seen in
SDR. Moreover, increases in glomerular TX production, VG
7 Month diabetic
—7 month TXI
7 Month diabetic
—2 month TXRa + IXI
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and fractional and absolute mesangial volume of SDR were
prevented by treatment for seven months with the TXI. By
contrast, GBM width of TXI-treated SDR was reduced relative
to untreated SDR, but not to control values. In a previous
study, Hora et al [5] demonstrated that treatment of diabetic
rats for 16 weeks beginning at the time of induction of diabetes,
with the TX!, OKY-046 prevented basement membrane thick-
ening. The reason for this difference between the present and
previous results [5] is not clear but may be related to the much
longer duration of diabetes in the present study (7 months
compared to 16 weeks) or to the finding in the previous study
that OKY-046 reduced plasma glucose in the diabetic rats [5]. In
the present study no effect of the TX! was noted on plasma
glucose.
Administration of the same daily dose of TX! begun after five
months of diabetes and given for two months to SDR with
established albumiriuria failed to suppress increases in UAIb
compared to values in age-matched untreated SDR. This regi-
men, begun in a delayed fashion after induction of diabetes, also
only partially suppressed glomerular TX production and UTX
excretion of SDR. It is possible that higher doses of the TX!
alone or a longer period of treatment of five months of SDR with
established albuminuria may have been effective. Unfortu-
nately, higher doses of the TXI were not well tolerated by the
diabetic rats. Accordingly, as an alternative approach to assess
the role in five month SDR of residual increases in glomerular
TX and/or prostaglandin (PG) endoperoxides in the pathogen-
esis of albuminuria and structural changes in the glomerulus,
combined treatment with a TX! and a TXRA was given. The
TXRA employed in this study, Bay U-3405, is a potent orally
administered TXA2/endoperoxide receptor antagonist which
competitively inhibits platelet aggregation, vasoconstriction,
bronchoconstriction and coronary artery thrombosis [38—41].
The dose employed prevented the decline of GFR otherwise
induced by infusion of the TX mimetic, U46619 in control rats.
In contrast to the effects of the TX! alone, combined adminis-
tration of the TX! and TXRA to five month SDR attenuated the
increases in UAIb and fractional CAIb. This regimen also atten-
uated mesangial expansion, but did not alter GBM width or VG
compared to untreated SDR. Combined treatment of SDR with
the TX! and TXRA reduced UTX and glomerular TX production
to values comparable to those in SDR treated with the TX!
alone. Since Bay U-3405 blocks the interaction of both TXA2
and PG endoperoxides with receptor sites and may also shunt
endoperoxides from TX production to that of other prostanoids
[42], the current results do not distinguish which if any of these
actions, contributed to the amelioration of glomerular injury. It
is possible that more prolonged treatment with this regimen
might have resulted in more pronounced amelioration of albu-
minuria, a possibility currently under study.
The histologic changes in glomeruli of the seven month SDR
treated with TX! plus TXRA for two months are qualitatively
similar to previous findings in the SDR treated by pancreatic
transplantation [28, 30, 31, 43, 44]. Thus, two months after
pancreatic transplantation, UAIb and mesangial expansion were
reduced with no change in GBM thickness. The failure to
observe a reduction in GBM thickness may be in part related to
the longer half life of basement membrane components (200
days) compared to mesangial matrix proteins [45]. However,
the failure in the present study 10 prevent GBM thickening
when TX! was given from the time of induction of diabetes to
the time of sacrifice at seven months suggests that factors other
than, or in addition to TX, are involved in this process.
Whatever the mechanism, our findings support the positive
correlation between expansion of the mesangial matrix and the
development of albuminuria reported in other studies of human
and experimental diabetes [26, 29—33, 38—46]. !t is possible that
an increased flux of albumin through the mesangium stimulates
matrix protein production by mesangial cells, as previously
suggested [47]. Thus, expansion of the mesangium may be a
secondary response to altered glomerular permselectivity
rather than a primary event, and is certainly not unique to
diabetic glomerulopathy. However, recent studies have raised
the possibility that TX may have direct effects on mesangial
matrix production. Thus, the TX mimetic U46619 increases
fibronectin production by human mesangial cells in culture [48].
We have similarly observed increased fibronectin production by
rat glomerular mesangial cells in culture exposed to a TX
mimetic [49]. Thus, it is possible that increased glomerular TX
production leads to alterations in both glomerular structure and
function in diabetes.
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